XENE (Xenon Pharmaceuticals) Moat Score: 5/10 (As of Jun. 30, 2026)


XENE Xenon Pharmaceuticals Inc XENE
25 GF Score
Price $60.13
! 5 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals Moat Score?

Xenon Pharmaceuticals XENE +0.66% 25 Moat Score is 5 as of Jun. 30, 2026. GuruFocus rates XENE with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,401 Biotechnology companies, Xenon Pharmaceuticals ranks better than 96.72% on this metric.

Xenon Pharmaceuticals has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Xenon Pharmaceuticals has Narrow Moat: Xenon Pharmaceuticals Inc has valuable intellectual property and strong R&D capabilities. However, it lacks significant market share, customer loyalty, and cost advantages, limiting its competitive edge to a solid narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Xenon Pharmaceuticals might have Narrow Moat - Solid narrow moat.

Xenon Pharmaceuticals  (NAS:XENE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Xenon Pharmaceuticals Moat Score Related Terms

XENE vs DFTX, LEGN, TVTX: Moat Score Comparison

For the Biotechnology subindustry, Xenon Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenon Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Moat Score falls into.


XENE
25GF Score
Xenon Pharmaceuticals Inc XENE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Xenon Pharmaceuticals (XENE) has a Moat Score of 5 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Xenon Pharmaceuticals ranks #46 out of 1401 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Xenon Pharmaceuticals' Moat Score too high?
Xenon Pharmaceuticals' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Xenon Pharmaceuticals' value of 5 is 150% above this industry median. Based on the distribution chart, Xenon Pharmaceuticals ranks #46 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xenon Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Xenon Pharmaceuticals' Moat Score compare to DFTX and LEGN?
According to the Biotechnology industry distribution chart, Xenon Pharmaceuticals ranks #46 out of 1401 companies for Moat Score. This places Xenon Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Xenon Pharmaceuticals' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xenon Pharmaceuticals's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xenon Pharmaceuticals's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenon Pharmaceuticals stock overvalued right now?
Xenon Pharmaceuticals (XENE) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Xenon Pharmaceuticals' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Xenon Pharmaceuticals (XENE), the current Moat Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xenon Pharmaceuticals Business Description

Other Exchanges XP0:Germany
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
25GF Score

Get the complete analysis for XENE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.13
Price